Ventavis Related Clinical Trials
Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis [Terminated]
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction [Terminated]
Aerosolized Randomized Iloprost Study II (AIR – II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension [Completed]
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension [Active, not recruiting]
Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension [Recruiting]
Iloprost Power 15 in Pulmonary Arterial Hypertension [Recruiting]
Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery [Recruiting]
Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis [Completed]
Effect of Iloprost on Gas Exchange and Pulmonary Mechanics in Patients With COPD in Patients With COPD [Recruiting]
Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension [Terminated]
Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants. [Recruiting]
The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc 15 Setting [Recruiting]
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in PAH Subjects [Not yet recruiting]
Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction and Exercise Capacity at High Altitude [Recruiting]
Long-Term Observational Study of Ventavis in Pulmonary Hypertension [Recruiting]
Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension [Recruiting]
Iloprost Power Disc-15 in Pulmonary Arterial Hypertension [Recruiting]
Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention [Completed]
Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH) [Completed]
Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction at Altitude [Not yet recruiting]
Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis [Not yet recruiting]
Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH) [Active, not recruiting]
Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease [Recruiting]
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension [Completed]
Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost [Recruiting]
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis [Completed]
High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis [Recruiting]
Inhaled Prostacyclin for Adult Respiratory Distress Syndrome (ARDS) and Pulmonary Hypertension [Recruiting]
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) [Recruiting]
Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. [Not yet recruiting]
|
